Elsevier

Fertility and Sterility

Volume 81, Issue 6, June 2004, Pages 1604-1616
Fertility and Sterility

Male factor
Pregnancy course and outcome after intracytoplasmic sperm injection: a controlled, prospective cohort study

https://doi.org/10.1016/j.fertnstert.2003.10.053Get rights and content
Under an Elsevier user license
open archive

Abstract

Objective

To determine pregnancy course and major malformation rate after intracytoplasmic sperm injection (ICSI).

Design

Prospective, controlled, multicenter, nationwide German cohort study.

Setting

Tertiary infertility centers in Germany.

Patient(s)

Three thousand three hundred seventy-two children and fetuses and 8,016 children and fetuses after the 16th week of gestation in pregnancies after ICSI and natural conception, respectively.

Intervention(s)

Standardized prospective follow-up.

Main outcome measure(s)

Major malformation rate.

Result(s)

The major malformation rate was 8.7% (295/3,372) for the ICSI cohort and 6.1% (488/8,016) for the population-based control cohort (relative risk, 1.44 [1.25–1.65]). After adjustment for risk factors, the risk declined (adjusted odds ratio, 1.24 [95% CI, 1.02–1.50]). Regarding singletons, there was a significant difference for birth weight and gestational age, with a higher number of preterm and low birth weight children in pregnancies achieved after ICSI.

Conclusion(s)

Children who are born after intracytoplasmic sperm injection have an increased risk of a major congenital malformation compared with those born after spontaneous conception. This risk is mainly due to paternal and maternal risk factors, which are more prevalent in couples who use ICSI for reproduction. An infertility-linked risk is highly probable for the observed findings. A technique-related risk, however, cannot be ruled out.

Keywords

Intracytoplasmic sperm injection
follow-up study
major malformation
pregnancy course

Cited by (0)

Supported primarily by Serono GmbH. Additional sponsors were Organon GmbH, ASTA Medica AG, Ferring Arzneimittel GmbH, Gück Zellkulturbedarf GmbH, Takeda Pharma GmbH, Gynemed Medizinprodukte GmbH & Co. KG, MTG Medical Technology Vertriebs GmbH, and OCTAX Microscience GmBH. Dr. Ludwig received a personal grant from the Rockstroh Stiftung of the Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. The study was also sponsored substantially by the IVF centers in Germany themselves.